Granisetron: New insights into its use for the treatment of chemotherapy-induced nausea and vomiting

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 9, 2003, Pages 1563-1571

  Tan, Marianne ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

5 HT3 receptor antagonists; Chemotherapy; Dolasetron; Emesis; Granisetron; Nausea; Ondansetron

Indexed keywords

ADRENERGIC RECEPTOR; ALIZAPRIDE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; DEBRISOQUINE; DEXAMETHASONE; DOLASETRON MESILATE; FLUOXETINE; GRANISETRON; HALOPERIDOL; HISTAMINE RECEPTOR; HYDRODOLASETRON; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; OPIATE RECEPTOR; PHENOTHIAZINE DERIVATIVE; QUINIDINE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN RECEPTOR; SPARTEINE; TROPISETRON; UNINDEXED DRUG;

ACUTE DISEASE; ARTICLE; ASTHENIA; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; NAUSEA AND VOMITING; NERVE FIBER; NEUROTOXICITY; NONHUMAN; PHARMACOGENOMICS; POSTOPERATIVE NAUSEA AND VOMITING; PROPHYLAXIS; SEDATION; VERTIGO; VISUAL DISORDER;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; GRANISETRON; HUMANS; INDOLES; NAUSEA; ONDANSETRON; QUINOLIZINES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0141851852     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.9.1563     Document Type: Article

References (41)

1. SCHNELL FM: Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist (2003) 8:187-198.
2. AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS: ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am. J. Health Syst. Pharm. (1999) 56:729-764.
3. CAMPOS D, PEREIRA JR, REINHARDT RR et al.: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol. (2001) 19:1759-1767.
4. GRALLA RJ, OSOBA D, KRIS MG et al.: Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. Am. Soc. Clin. Oncol. J. Clin. Oncol. (1999) 17:2971-2994.
5. 3 antagonists. Br. J. Cancer. (1997) 76:1055-1061.
6. Roche Pharmaceuticals: Kytril® (granisetron hydrochloride injection) package insert. Roche Pharmaceuticals, Nutley, NJ, USA (2002).
7. 3 receptor antagonism in the control of cytostatic drug-induced emesis. Eur. J. Cancer (1990) 26(Suppl. 1):S8-S11.
8. SANGER GJ, NELSON DR: Selective and functional 5-hydroxytryptamine 3 receptor antagonism by BRL 43694 (granisetron). Eur. J. Pharmacol. (1989) 159:113-124.
9. VAN WIJNGAARDEN I, TULP MT, SOUDIJN W: The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol. (1990) 188:301-312.
10. BLOWER PR: Granisetron: relating pharmacology to clinical efficacy. Support Care Cancer (2003) 11:93-100.
11. 3 receptor antagonist. Br. J. Clin. Pharmacol. (1998) 25:106P-107P
12. UPWARD JW, ARNOLD BD, LINK C, PIERCE DM, ALLEN A, TASKER TC: The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur. J. Cancer. (1990) 26(Suppl. 1):S12-S15.
13. BLOWER P, AAPRO M: Granisetron versus ondansetron: is it a question of duration of 5-HT3 receptor blockade? Br. J. Cancer (2002) 86:1662-1663.
14. BLOOMER JC, BALDWIN SJ, SMITH GJ, AYRTON AD, CLARKE SE, CHENERY RJ: Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br. J. Clin. Pharmacol. (1994) 38:557-566.
15. KAISER R, SEZER O, PAPIES A et al.: Patient-tailored antiemetic treatment with 5-hydroxytryptamine Type 3 receptor antagonists according to cytochrome P450 2D6 genotypes. J. Clin. Oncol. (2002) 20:2805-2811.
16. ADDELMAN M, ERLICHMAN C, FINE S, WARR D, MURRAY C: Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J. Clin. Oncol. (1990) 8:337-341.
17. MIKAWA K, TAKAO Y, NISHINA K, SHIGA M, MAEKAWA N, OBARA H: Optimal dose of granisetron for prophylaxis against postoperative emesis after gynecological surgery. Anesth. Analg. (1997) 85:652-656.
18. WILSON AJ, DIEMUNSCH P, LINDEQUE BG et al.: Single-dose i.v. granisetron in the prevention of postoperative nausea and vomiting. Br. J. Anaesth. (1996) 76:515-518.
19. TAYLOR AM, ROSEN M, DIEMUNSCH PA, THORIN D, HOUWELING PL: A double-blind, parallel-group, placebo-controlled, dose-ranging, multicenter study of intravenous granisetron in the treatment of postoperative nausea and vomiting in patients undergoing surgery with general anesthesia. J. Clin. Anesth. (1997) 9:658-663.
20. SPITZER TR, FRIEDMAN CJ, BUSHNELL W, FRANKEL SR, RASCHKO J: Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant. (2000) 26:203-210.
21. PEREZ EA, HESKETH P, SANDBACH J et al.: Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J. Clin. Oncol. (1998) 16:754-760.
22. GRALLA RJ, NAVARI RM, HESKETH PJ et al.: Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J. Clin. Oncol. (1998) 16:1568-1573.
23. TAN M, XU R, SETH R: Granisetron versus dolasetron for acute nausea and vomiting in high and moderately-high emetogenic chemotherapy. Presented at the MASCC/ISOO 14th International Symposium; Boston, MA, USA June 23-26 (2002) (Poster 117).
24. DE WIT R, DE BOER AC, VD LINDEN GH, STOTER G, SPARREBOOM A, VERWEIJ J: Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br. J. Cancer (2001) 85:1099-1101.
25. CARMICHAEL J, KEIZER HJ, CUPISSOL D, MILLIEZ J, SCHEIDEL P, SCHINDLER AE: Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs (1998) 9:381-385.
26. NAVARI RM, KAPLAN HG, GRALLA RJ, GRUNBERG SM, PALMER R, FITTS D: Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J. Clin. Oncol. (1994) 12:2204-2210.
27. HESKETH PJ, CREWS JR, COHEN R, BLACKBURN LM, FRIEDMAN CJ: Antiemetic efficacy of single-dose oral granisetron (1 mg versus 2 mg) with moderately emetogenic chemotherapy. Cancer J. (2000) 6:157-161.
28. AAPRO MS, THUERLIMANN B, SESSA C, DE PREE C, BERNHARD J, MAIRACH R: A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann. Oncol. (2003) 14:291-297.
29. LATREILLE J, PATER J, JOHNSTON D et al.: Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (1998) 16:1174-1178.
30. NAVARI RM, REINHARDT RR, GRALLA RJ et al.: Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N. Engl. J. Med. (1999) 340:190-195.
31. Merck & Co.: Emend® (aprepitant capsules) package insert. Merck & Co., Whitehouse Station, NJ, USA (2003).
32. GRUNBERG S, HAJDENBERG J, CHARU V: Palonosteron is active in preventing acute and delayed emesis following moderately emetogenic chemotherapy: results of a Phase III trial. Support Care Cancer (2002) 10:(Abstract P-113).
33. KURYSHEV YA, BROWN AM, WANG L, BENEDICT CR, RAMPE D: Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J. Pharmacol. Exp. Ther. (2000) 295:614-620.
34. KEEFE DL: The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? Oncologist (2002) 7:65-72.
35. CARMICHAEL J: The cardiovascular safety of high-dose intravenous granisetron in cancer pateints receiving highly emetogenic chemotherapy. Presented at the AMSCC/ISOO 14th International Symposium; Boston, MA, USA June 23-26 (2002).
36. WATANABE H, HASEGAWA A, SHINOZAKI T, ARITA S, CHIGIRA M: Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother. Pharmacol. (1995) 35:278-282.
37. JANTUNEN IT, KATAJA VV, MUHONEN TT, PARVIAINEN T: Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother. Pharmacol. (1996) 37:502-504.
38. Aventis Pharmaceuticals: Anzement® (dolasetron mesylate injection) package insert. Aventis Pharmaceuticals, Kansas City, MO, USA (2000).
39. CLARK CD, ABEL SR, DEMPSEY CL, SHILLINGTON AC, BYUN MH: A cost analysis of ondansetron and granisetron in the management of chemotherapy-induced nausea and vomiting. Hesp. Pharmacology (1998) 33:198-204.
40. CHAWLA SP, GRUNBERG SM, GRALLA RJ et al.: Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer (2003) 97:2290-2300.
41. GlaxoSmithKhne: Zofran® (ondansetron HCI injection) package insert. GlaxoSmithKline, Research Triangle Park, NC, USA (2001).